JP2009543800A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543800A5
JP2009543800A5 JP2009519633A JP2009519633A JP2009543800A5 JP 2009543800 A5 JP2009543800 A5 JP 2009543800A5 JP 2009519633 A JP2009519633 A JP 2009519633A JP 2009519633 A JP2009519633 A JP 2009519633A JP 2009543800 A5 JP2009543800 A5 JP 2009543800A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
individual
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009519633A
Other languages
English (en)
Japanese (ja)
Other versions
JP5048772B2 (ja
JP2009543800A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073144 external-priority patent/WO2008008772A2/en
Publication of JP2009543800A publication Critical patent/JP2009543800A/ja
Publication of JP2009543800A5 publication Critical patent/JP2009543800A5/ja
Application granted granted Critical
Publication of JP5048772B2 publication Critical patent/JP5048772B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009519633A 2006-07-12 2007-07-10 線維性疾患及びケロイドを治療及び抑制する方法 Expired - Fee Related JP5048772B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83027906P 2006-07-12 2006-07-12
US60/830,279 2006-07-12
US84904106P 2006-10-02 2006-10-02
US60/849,041 2006-10-02
PCT/US2007/073144 WO2008008772A2 (en) 2006-07-12 2007-07-10 Methods for treating and limiting fibrotic disorders and keloids

Publications (3)

Publication Number Publication Date
JP2009543800A JP2009543800A (ja) 2009-12-10
JP2009543800A5 true JP2009543800A5 (enExample) 2012-07-19
JP5048772B2 JP5048772B2 (ja) 2012-10-17

Family

ID=38924094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519633A Expired - Fee Related JP5048772B2 (ja) 2006-07-12 2007-07-10 線維性疾患及びケロイドを治療及び抑制する方法

Country Status (13)

Country Link
US (1) US20110028398A1 (enExample)
EP (1) EP2051727A4 (enExample)
JP (1) JP5048772B2 (enExample)
KR (1) KR101267217B1 (enExample)
AU (1) AU2007272578B2 (enExample)
BR (1) BRPI0714383A2 (enExample)
CA (1) CA2657263A1 (enExample)
CR (1) CR10552A (enExample)
DO (1) DOP2009000005A (enExample)
MX (1) MX2009000359A (enExample)
NZ (1) NZ574717A (enExample)
SG (1) SG173369A1 (enExample)
WO (1) WO2008008772A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617431B1 (en) 2007-01-10 2017-04-12 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation キナーゼ阻害薬およびその使用
WO2010027831A1 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
BRPI0922448A2 (pt) 2008-12-10 2021-02-17 Purdue Research Foundation inibidor com base em peptídeo penetrante celular de quinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2013134177A1 (en) * 2012-03-05 2013-09-12 Capstone Therapeutics Corp. Methods and compositions for improving spinal surgery outcomes
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
US20170275650A1 (en) * 2014-07-22 2017-09-28 The Regents Of The University Of California Endosomal escape domains for delivery of macromolecules into cells
KR101667900B1 (ko) * 2016-01-15 2016-10-21 테고사이언스 (주) 켈로이드성 피부 또는 켈로이드 흉터 진단용 바이오마커 단백질 및 이의 이용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) * 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US7556722B2 (en) * 1996-11-22 2009-07-07 Metzger Hubert F Electroplating apparatus
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AU2001249214A1 (en) * 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ES2432225T3 (es) * 2001-08-23 2013-12-02 Arizona Board Of Regents Reactivos y procedimientos para terapias del músculo liso
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
ATE332703T1 (de) * 2003-02-21 2006-08-15 Univ Arizona Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
CA2542639A1 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
JP2009033589A (ja) * 2007-07-30 2009-02-12 Ricoh Co Ltd 画像形成装置、プログラムおよび記録媒体

Similar Documents

Publication Publication Date Title
JP2009543800A5 (enExample)
PH12022550232A1 (en) Gipr-agonist compounds.
JP2013516427A5 (enExample)
RU2015132208A (ru) Модуляция экспрессии гентингтина
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
NO20082448L (no) Kombinasjoner av angiopoietin-2 antagonister og VEGF-A, KDR og/eller FLT1 antagonist for behandling av cancer
KR20180118259A (ko) 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법
JP2006520611A5 (enExample)
CA2730789A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
JPWO2019156137A5 (enExample)
JP2016505612A5 (enExample)
JP2012505154A5 (enExample)
WO2017050052A1 (zh) Syk作为肝纤维化/肝硬化治疗靶点的应用
BR112022009898A2 (pt) Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
Kopp et al. Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
JP2009500045A5 (enExample)
JP2016516054A5 (enExample)
WO2011060534A8 (en) Trim5alpha mutants and uses thereof
CN106222173B (zh) circRNA MNCR在调节心肌细胞坏死和心肌缺血损伤中的作用
Shi et al. Local application of MDL28170-loaded PCL film improves functional recovery by preserving survival of motor neurons after traumatic spinal cord injury
JP2017524727A5 (enExample)
EA200700772A1 (ru) Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний
Kelly Diarrhoea and AIDS: recent developments in the African setting
JP5149528B2 (ja) C型肝炎ウイルスの複製を制御するマイクロrna